Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604571 | 1.00 | SIRT2 (0.48) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL13604580 | 0.92 | SIRT2 (0.46) | SIRT2USP30NPC1ACKR3RAB9A | |
| SCHEMBL13604609 | 0.87 | SCN9A (0.44) | SIRT2USP30ACKR3JAK2JAK1 | |
| SCHEMBL4491921 | 0.86 | JAK2 (0.49) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL4480759 | 0.86 | JAK2 (0.49) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL13604563 | 0.86 | JAK2 (0.49) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL13604584 | 0.83 | SIRT2 (0.46) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL4489634 | 0.83 | SIRT2 (0.46) | SIRT2USP30HDAC8NPC1ACKR3 | |
| SCHEMBL4484577 | 0.79 | SIRT2 (0.48) | SIRT2HDAC8 | |
| SCHEMBL5927859 | 0.76 | JAK1 (0.42) | USP30JAK2JAK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | SIRT2 1655/4885USP30 2045/4885HDAC8 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.